CompletedPHASE1, PHASE2NCT00569010

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Studying C syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Jean-Pierre Issa, MD
M.D. Anderson Cancer Center
Intervention
Azacitidine(drug)
Enrollment
36 target
Eligibility
18 years · All sexes
Timeline
20052009

Study locations (1)

Collaborators

Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00569010 on ClinicalTrials.gov

Other trials for C syndrome

Additional recruiting or active studies for the same condition.

See all trials for C syndrome

← Back to all trials